PD-1/PD-L1 inhibitor-induced hyponatremia: a real-world pharmacovigilance analysis using FAERS database
{{output}}
Background: With the increasing use of programmed cell death protein 1 and programmed cell death ligand 1 (PD-1/PD-L1) inhibitors in cancer treatment, hyponatremia has emerged as a notable adverse event associated with this class... ...
